'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Dr Reddys Laboratories has increased 16.45% to Rs 8038.2 crore. Sales of Pharmaceutical Services segment has gone up 16.26% to Rs 1,119.00 crore (accounting for 13.48% of total sales). Sales of Global Generics segment has gone up 17.19% to Rs 7,163.60 crore (accounting for 86.30% of total sales). Sales of Others segment has gone down 73.79% to Rs 17.90 crore (accounting for 0.22% of total sales). Inter-segment sales rose Rs 241.20 crore to Rs 262.30 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 18.32% to Rs 4,777.20 crore. PBIT of Pharmaceutical Services segment rose 100.08% to Rs 252.10 crore (accounting for 5.28% of total PBIT). PBIT of Global Generics segment rose 16.18% to Rs 4,516.20 crore (acco...
Pleaselogin & subscribe to view the full report.
More Reports
-
(06-May-2025)
Mahindra & Mahindra
OP surged 19.79%
-
(06-May-2025)
Coforge
Revenue up 47.08% YoY to Rs 3410 cr in Q4FY2025
-
(06-May-2025)
Indian Hotels Co
Revenue up 27.3% YoY, Net Profit up 25.0% YoY in Q4FY2025
-
(05-May-2025)
Epigral
Capex in FY2025 was Rs 195 crore
|
|